Captopril kinetics

Area of Science:

• Pharmacology
• Clinical Pharmacy

Background:

• Captopril is an angiotensin-converting enzyme (ACE) inhibitor used for its antihypertensive properties.
• Understanding its pharmacokinetic profile is crucial for optimizing therapeutic use.

Purpose of the Study:

• To determine the pharmacokinetic parameters of captopril following oral and intravenous administration.
• To assess the absorption and bioavailability of oral captopril.

Main Methods:

• Five healthy subjects received 10-mg doses of captopril orally and intravenously.
• Blood and urine samples were collected to analyze drug levels and excretion.
• Pharmacokinetic data were analyzed using a three-compartment model.

Main Results:

• Intravenous dosing showed a triexponential decay in blood levels.
• The mean blood half-life during the beta phase was 1.9 hours.
• Absolute oral absorption was 71%, with an absolute oral bioavailability of 62%.

Conclusions:

• Captopril exhibits predictable pharmacokinetic behavior after intravenous and oral administration.
• The study provides key data on captopril's absorption, distribution, and elimination, supporting its clinical application.